Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor

Comparative Structural and Functional Studies of 4-(Thiazol- 5-Yl)-2-(Phenylamino)Pyrimidine-5-Carbonitrile Cdk9 Inhibitors Suggest the Basis for Isotype Selectivity.

2.7.11.22, CELL DIVISION PROTEIN KINASE 2, P33 PROTEIN KINASE

PGSMENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNHPNIVKLLDVIHTENKLY
LVFEFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVR
TY(TPO)HEVVTLWYRAPEILLGCKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSM
PDYKPSFPKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL

PGSMENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNHPNIVKLLDVIHTENKLY
LVFEFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVR
TYTHEVVTLWYRAPEILLGCKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPDYK
PSFPKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL

SVNEVPDYHEDIHTYLREMEVKCKPKVGYMKKQPDITNSMRAILVDWLVEVGEEYKLQNETLHLAVNYIDRFLSSMSVLR
GKLQLVGTAAMLLASKFEEIYPPEVAEFVYITDDTYTKKQVLRMEHLVLKVLTFDLAAPTVNQFLTQYFLHQQPANCKVE
SLAMFLGELSLIDADPYLKYLPSVIAAAAFHLALYTVTGQSWPESLIRKTGYTLETSKPCMLDLHQTYLKAPQHAQQSIR
EKYKNSKYHGVSLLNPPETLNL

SVNEVPDYHEDIHTYLREMEVKCKPKVGYMKKQPDITNSMRAILVDWLVEVGEEYKLQNETLHLAVNYIDRFLSSMSVLR
GKLQLVGTAAMLLASKFEEIYPPEVAEFVYITDDTYTKKQVLRMEHLVLKVLTFDLAAPTVNQFLTQYFLHQQPANCKVE
SLAMFLGELSLIDADPYLKYLPSVIAAAAFHLALYTVTGQSWPESLIRKTGYTLESLKPMLLDLHQTYLKAPQHAQQSIR
EKYKNSKYHGVSLLNPPETLNV

COCRYSTALS WERE GROWN IN 1-1.25M AMMONIUM SULFATE, 0.5-0.9M KCL, 100MM HEPES, PH 7.0, 5MM DTT AND IN THE PRESENCE OF COMPOUND.

HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR STAUROSPORINE

HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160

CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITHCELL CYCLE-REGULATORY PROTEIN CKSHS1

HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR PURVALANOL B

THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[3- HYDROXYANILINO]-6,7- DIMETHOXYQUINAZOLINE

HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR HYMENIALDISINE

HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058

HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027

THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND

CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDANT KINASE 2

CYCLIN A - CYCLIN-DEPENDENT KINASE 2 COMPLEX

CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) INCOMPLEX WITH PHOSPHO-CDK2

THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH AN OXINDOLE INHIBITOR

THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLEINHIBITOR

CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 ( CDK2)IN COMPLEX WITH THE INHIBITOR H717

HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR

PCDK2/CYCLIN A IN COMPLEX WITH MGADP, NITRATE AND PEPTIDE SUBSTRATE

HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2-AMINO-6-(3'-METHYL-2'-OXO)BUTOXYPURINE

CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR

CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR

HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[(R)-PYRROLIDINO-5'-YL ]METHOXYPURINE

HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[CYCLOHEX-3-ENYL] METHOXYPURINE

STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058

STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094

STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086

STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102

CDK2/CYCLINA IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F

CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM E2F

CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53

CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27

CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107

PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A

THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH 4-[(6-AMINO-4-PYRIMIDINYL)AMINO] BENZENESULFONAMIDE

CRYSTAL STRUCTURE OF HUMAN CDK2 (UNPHOSPHORYLATED) INCOMPLEX WITH PKF049-365

CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO-1,2- DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO} BENZENESULFONAMIDE

CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N- METHYL-{4-[2-(7-OXO-6,7-DIHYDRO-8H-[1,3]THIAZOLO [5,4-E]INDOL-8-YLIDENE)HYDRAZINO]PHENYL} METHANESULFONAMIDE

CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(2 ,2-DIOXIDO-1,3-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO] METHYLENE}-5-(1,3-OXAZOL-5-YL)-1,3-DIHYDRO-2H- INDOL-2-ONE

CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2 -OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}- N-(1,3-THIAZOL-2-YL)BENZENESULFONAMIDE

CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4 -({[AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]METHYLENE}-2 -OXO-2,3-DIHYDRO-1H-INDOLE

STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5- NITROSO-6-AMINOPYRIMIDINE INHIBITOR

STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR

IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN -DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE- BASED HYBRIDISATION

CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE -PHE-NH2

CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN -(M-CL-PHE)-NH2

CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE -(P-F-PHE)-NH2

CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN -(P-F-PHE)-NH2

THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH ATRISUBSTITUTED NAPHTHOSTYRIL INHIBITOR

THE STRUCURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THEINHIBITOR 4,5,6,7-TETRABROMOBENZOTRIAZOLE (TBS)

CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2COMPLEXED WITH A NUCLEOSIDE INHIBITOR

THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO-CDK2/CYCLIN A

APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2

HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-(2,5-DICHLORO-THIOPHEN-3-YL)-PYRIMIDIN -2-YLAMINE

HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN- 2-YLAMINE

HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR N-[4-(2,4-DIMETHYL-THIAZOL-5-YL) PYRIMIDIN-2-YL]-N'-HYDROXYIMINOFORMAMIDE

HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR [4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN -2-YL]-(4-TRIFLUOROMETHYL-PHENYL)-AMINE

HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 3-[4-(2,4-DIMETHYL-THIAZOL-5-YL)- PYRIMIDIN-2-YLAMINO]-PHENOL

HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-[4-(4-METHYL-2-METHYLAMINO-THIAZOL-5- YL)-PYRIMIDIN-2-YLAMINO]-PHENOL

HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR [4-(2-AMINO-4-METHYL-THIAZOL-5-YL)- PYRIMIDIN-2-YL]-(3-NITRO-PHENYL)-AMINE

HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)- PYRIMIDIN-2-YL]-N',N'-DIMETHYL-BENZENE-1,4-DIAMINE

CRYSTAL STRUCTURE OF CDK2 WITH INHIBITOR

PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX

CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE INHIBITOR

CDK2 IN COMPLEX WITH AN IMIDAZO[1,2-B]PYRIDAZINE

STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137

STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227

CRYSTALS STRUCTURE OF HUMAN CDK2 IN COMPLEX WITH THE INHIBITOR OLOMOUCINE.

CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY-8-ISOPROPYL -9H-PURIN-2-YLAMINE AND MONOMERIC CDK2

THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E

SCREENING FOR FRAGMENT BINDING BY X-RAY CRYSTALLOGRAPHY

CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1,5-A]PYRIMIDINE INHIBITOR

CRYSTAL STRUCTURE OF CDK2 WITH AN AMINOIMIDAZO PYRIDINEINHIBITOR

HUMAN CDK2 IN COMPLEX WITH OLOMOUCINE II, A NOVEL 2 ,6,9-TRISUBSTITUTED PURINE CYCLIN-DEPENDENT KINASE INHIBITOR

HUMAN CYCLIN-DEPENDENT KINASE 2 IN COMPLEX WITH ROSCOVITINE

HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DPH-042562

HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DIN-234325

HUMAN CYCLIN DEPENDENT KINASE 2 (CKD2)COMPLEXED WITH DIN-232305

HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITHINDENOPYRAXOLE DIN-101312

HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 5-BROMO-INDIRUBINE

HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 4-HYDROXYPIPERINDINESULFONYL-INDIRUBINE

STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611

STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529

STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873

STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032

STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514

DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN

CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR

THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA-LINKED ATP ANALOGUE

CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6

MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE

4-ARYLAZO-3,5-DIAMINO-1H-PYRAZOLE CDK INHIBITORS: SAR STUDY, CRYSTAL STRUCTURE IN COMPLEX WITH CDK2, SELECTIVITY, AND CELLULAR EFFECTS

HUMAN CDK2 IN COMPLEX WITH ISOPENTENYLADENINE

STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A INCOMPLEX WITH THE INHIBITOR NU6271

STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR

STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H- L83V-H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR

CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH MACROCYCLIC AMINOPYRIMIDINE

CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX WITH CYCLIN B

REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS

CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR

IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT -BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.

CDK2 IN COMPLEX WITH AN IMIDAZOLE PIPERAZINE

STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE, COMPOUND 5B

STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE, COMPOUND 5C

CDK2 IN COMPLEX WITH THE IMIDAZOLE PYRIMIDINE AMIDE, COMPOUND (S)-8B

FRAGMENT-BASED DISCOVERY OF THE PYRAZOL-4-YL UREA ( AT9283), A MULTI-TARGETED KINASE INHIBITOR WITH POTENT AURORA KINASE ACTIVITY

TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN

STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125

STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO- 1-METHYL-4,5-DIHYDRO-1H-PYRAZOLO[4,3-H] QUINAZOLINE-3-CARBOXYLIC ACID

STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A

OPTIMISATION OF 6,6-DIMETHYL PYRROLO 3,4-C PYRAZOLES : IDENTIFICATION OF PHA-793887, A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING

STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(4,3-H ) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR

1ST PUBLICATION TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN 2ND PUBLICATION DESIGN, SYNTHESIS AND EVALUATION OF 2-METHYL- AND 2-AMINO-N-ARYL-4,5- DIHYDROTHIAZOLO (4,5-H)QUINAZOLIN-8-AMINES AS RING- CONSTRAINED 2-ANILINO-4-(THIAZOL-5-YL)PYRIMIDINE CDK INHIBITORS

DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL- 5-YL)PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS

CDK2 IN COMPLEX WITH 3-AMINO-6-(4-{[2-(DIMETHYLAMINO )ETHYL]SULFAMOYL}-PHENYL)-N-PYRIDIN-3-YLPYRAZINE-2- CARBOXAMIDE

STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2 -AMINO-4-HETEROARYL-PYRIMIDINE INHIBITOR

STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2 -AMINO-4-HETEROARYL-PYRIMIDINE INHIBITOR

CYCLIN-DEPENDENT KINASE 2 (E.C.2.7.11.22), CYCLIN-A2

TRANSFERASE-CELL CYCLE COMPLEX, CDK-CYCLIN COMPLEX, CYCLIN A, CYCLIN- DEPENDENT KINASE 2, STRUCTURE-BASED DRUG DESIGN